~ Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas ~ ~ SImmetry+ combines 3D-printed titanium implants, a robust joint decorticator, and a streamlined bone graft delivery system to offer treatment solutions aligned with established fusion principles ~ ~ Immediate revenue impact opportunity while significantly advancing Tenon's competitive position in redefining SI joint fusion with a multi-approach portfolio in rapidly expanding sacro-pelvic market ~ LOS GATOS, CA / ACCESS Newswire / December 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced the completion of the first clinical procedures utilizing the Company's new SImmetry+ SI Joint Fusion System. Ali Araghi, DO, Orthopedic Spine Surgeon in Phoenix, Arizona, Brian Fiani, DO Board Certified Neurosurgeon in Tampa, FL.

IQVIA (NYSE: IQV - Get Free Report) and Tenon Medical (NASDAQ: TNON - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Analyst Recommendations This is a summary of recent recommendations

LOS GATOS, CA / ACCESS Newswire / November 14, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the successful closing of its previously announced at-the-market private investment in public equity (the "PIPE") financing. As part of the closing of the PIPE, Tenon Medical has issued an aggregate of 2,217,904 shares of common stock (the "Issued Shares") along with warrants (the "PIPE Warrants") to purchase an equal number of shares.

Tenon Medical, Inc. ( TNON ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Foster - CEO, President & Director Kevin Williamson - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners, Research Division Thomas McGovern Presentation Operator Greetings, and welcome to the Tenon Medical Third Quarter 2025 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded.

~ Record revenue of $1.2 million, a 32% year-over-year increase, reflecting record volume in Catamaran® SI Joint Fusion System procedures and the addition of SImmetry® SI Joint Fusion Product Sales ~ ~ SImmetry®+ alpha launch in Q4 2025 advances strategic portfolio ~ ~ Foundation set for sustained growth through portfolio diversification, commercial expansion and operational alignment ~ ~ Subsequent to quarter end the Company announced the pricing of a PIPE financing with an industry supportive investor cohort raising total gross proceeds of $2.85 million ~ LOS GATOS, CA / ACCESS Newswire / November 13, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today reported record financial results for the third quarter ended September 30, 2025. Financial Results and Business Updates Record revenue of $1.2 million, compared to $0.9 million in the third quarter of 2024.

~ Strategically Placed PIPE With Industry Supportive Investor Cohort ~ LOS GATOS, CA / ACCESS Newswire / November 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the pricing of an at-the-market private investment in public equity (the "PIPE") financing with several accredited investors for total gross proceeds of $2,850,000. The PIPE is designed to provide accretive capital through participation from strategic industry partners and members of Tenon's management team.

LOS GATOS, CA / ACCESS Newswire / November 3, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced plans to release financial results for the third quarter 2025 ended September 30, 2025 after market close on Thursday, November 13, 2025. The Company will also hold a conference call on the same day at 4:30 p.m.

~Clearance expands Company's competitive advantage of clinically proven, minimally invasive technologies to treat debilitating SI joint conditions from multiple surgical approaches~ ~SImmetry+'s New 3D printed titanium implants, robust joint decorticator, and simple bone graft delivery system provides physicians treatment options rooted in established fusion principles~ ~Company initiating alpha launch of SImmetry® + with select group of physician users to provide initial feedback to support broader launch~ LOS GATOS, CA / ACCESS Newswire / October 21, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SImmetry+ SI Joint Fusion System. The SImmetry+ System is indicated for sacroiliac (SI) joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis, providing physicians with treatment options rooted in established fusion principles.

~ Clinically Significant Patient Outcomes Demonstrate Improvements in Pain (VAS) and Disability (ODI), Along with High Patient Satisfaction and Safety Profile at 12-Month Analysis ~ ~ 83% of Patients Reaching 12 Month Radiographic CT Follow-up Showed Unequivocal Evidence of Fusion with Bridging Bone Across the SI Joint as Identified by an Independent Radiology Reviewer ~ ~Compelling Clinical Data from Catamaran Mainsail Study and Recently Acquired SiVantage Technology Portfolio Expected to Drive Exponential Growth in Rapidly Expanding Sacro-Pelvic Fusion Market ~ LOS GATOS, CA / ACCESS Newswire / September 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the second interim analysis publication from its ongoing MAINSAIL™ study, a prospective, single-arm, multi-center, post-market clinical trial evaluating clinical and radiographic outcomes in adult patients with sacroiliac (SI) joint disruptions or degenerative sacroiliitis treated with the Catamaran® SI Joint Fusion System. The Mainsail study is designed to enroll up to 50 patients, each followed for up to 24 months.

~Full Commercial Launch with Expanded Number of Instrument Sets and Field Support to Meet Growing Market Demand ~ ~ New SI Joint Fixation Device Offers a Reduced Profile in Implant Size Providing Physicians Choices for Varying Anatomy and Treatment Strategies with the Catamaran Technology ~ LOS GATOS, CA / ACCESS Newswire / August 19, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain sacro-pelvic disorders, today announced the full commercial market launch of its new Catamaran® SE SI Joint Fusion System. The Catamaran SE Fixation Device expands the Company's implant portfolio, providing physicians with a smaller implant option for sacroiliac (SI) joint fusion procedures.